Health-Related Quality of Life Among Patients with Relapsed or Refractory Multiple Myeloma Who Received Pomalidomide, Bortezomib, and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone - Results from the Phase 3 Optimismm Study
Katja Weisel(Universität Hamburg), Paul G. Richardson(Harvard University), Nicola Cascavilla, Alessandra Larocca(Cornell University), Kosei Matsue(Kameda Medical Center), Mohamed H. Zaki, Marek Hus(Medical University of Lublin), Meletios Α. Dimopoulos(Korea University), Münci Yağcı(Gazi University), Ercan Muelduer, Tsvetan Biyukov(Bristol-Myers Squibb (Switzerland)), Lara Grote(Bristol-Myers Squibb (United States)), Filiz Vural(Ege University), Л. П. Менделеева(National Research Center for Hematology Russian Academy of Medical Sciences), Xin Yu(University of South Florida), Peter D. Byeff(University College Dublin), Abraham S. Kanate(West Virginia University), Maria‐Theresa Krauth(Medical University of Vienna), Paula Rodríguez‐Otero(Clinica Universidad de Navarra), Peter Johnson(Western General Hospital), Supratik Basu, Philippe Moreau(Centre National de la Recherche Scientifique), Patrick Hayden, Shien Guo(Ithaka Harbors), Lea Purnomo, Dina Ben‐Yehuda(Hebrew University of Jerusalem), Pekka Anttila
Cited by 1
Related Papers
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Hematological findings and complications of <scp>COVID</scp>‐19
|American Journal of Hematology|2020|1.7k